Nascent Pharma Holdings (NASC) AI Stock Analysis

• Market Cap: $2.12M
• Dividend Yield: N/A
• Average Volume (3M): 35.25K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.48
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 75,841,990
• 10 Day Avg. Volume: 42,355
• 30 Day Avg. Volume: 35,253
• PEG Ratio: <0.01
• Price to Book (P/B): -0.16
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -9.39
• Enterprise Value/Market Cap: 4.84
• Enterprise Value/Revenue: 9.94
• Enterprise Value/Gross Profit: -6.46
• Enterprise Value/Ebitda: -1.03
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 30 Underperform
• Price Target: ―

Can B's overall score reflects significant financial struggles, including negative profitability and liquidity issues. Technical analysis shows some long-term stability but short-term weakness. The company's valuation metrics are poor, with negative earnings and no dividend yield, highlighting substantial risks.

Nascent Pharma Holdings Business Overview & Revenue Model

Company Description

Nascent Pharma Holdings, Inc. engages in the protection and commercialization of cannabis patents. It produces superfood drink mix products under the Longevity brand name. The company was formerly known as Can B Corp. and changed its name to Nascent Pharma Holdings, Inc. in September 2025. Nascent Pharma Holdings, Inc. was incorporated in 2005 and is based in Hicksville, New York.

How the Company Makes Money

Can B Corp generates revenue primarily through the sale of its hemp-derived products, which are distributed both through direct-to-consumer channels and wholesale distribution networks. The company leverages e-commerce platforms to reach a broad customer base and enhance its market presence. Key revenue streams include the sale of CBD oils, topicals, and other hemp-based wellness products. Can B Corp also capitalizes on strategic partnerships with retailers and distributors to expand its reach in various markets. Additionally, the company may engage in private label and white label manufacturing for other brands, providing another avenue for revenue generation. Factors contributing to its earnings include the growing consumer interest in natural health alternatives and the legalization and increasing acceptance of hemp-derived products in various regions.

Nascent Pharma Holdings Financial Statement Overview

Summary

Overall, Can B faces severe financial challenges, especially in terms of profitability and liquidity. The company has not only experienced declining revenues but also struggles with high operating losses and negative equity, posing significant risks to its financial health.

Income Statement

The income statement shows significant challenges with negative gross profit margins and consistently negative net income over the years. Revenue has been volatile, evidenced by a sharp decline from 2022 to 2023 and a further drop in TTM data. The company is struggling to achieve profitability, with negative EBIT and EBITDA margins.

Balance Sheet

The balance sheet indicates a weak financial position with negative stockholders' equity as of the latest TTM data, suggesting insolvency risks. The debt-to-equity ratio is not applicable due to negative equity, and the equity ratio is negative. These factors point to significant leverage and instability.

Cash Flow

Cash flow analysis shows some improvement in operating cash flow in TTM, but free cash flow remains negative. The operating cash flow to net income ratio is unhelpful given the negative net income. The company has not generated sufficient cash flow to cover its expenses consistently.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.03M	0.00	2.16M	6.69M	4.60M	1.71M
Gross Profit	-1.59M	-742.32K	358.70K	2.61M	2.99M	1.43M
EBITDA	-9.99M	-7.65M	-5.82M	-12.59M	-9.52M	-7.16M
Net Income	-13.26M	-10.20M	-9.74M	-14.92M	-12.17M	-8.88M
Balance Sheet
Total Assets	1.86M	299.54K	10.13M	15.56M	16.47M	3.91M
Cash, Cash Equivalents and Short-Term Investments	7.88K	5.96K	34.01K	73.19K	449.00K	457.80K
Total Debt	9.01M	8.30M	9.18M	9.34M	7.28M	2.08M
Total Liabilities	11.64M	13.02M	11.13M	12.86M	10.86M	2.44M
Stockholders Equity	-9.79M	-12.72M	-1.00M	2.70M	5.62M	1.48M
Cash Flow
Free Cash Flow	246.61K	-221.63K	-1.32M	-3.95M	-8.04M	-2.00M
Operating Cash Flow	246.61K	-221.63K	-1.30M	-3.95M	-7.32M	-1.95M
Investing Cash Flow	-9.97K	231.32K	-84.63K	0.00	-860.79K	-25.25K
Financing Cash Flow	-259.94K	-27.82K	1.35M	3.57M	8.17M	2.38M

Nascent Pharma Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.03
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NASC, the sentiment is Positive. The current price of 0.03 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and above the 200-day MA of 0.02, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.20 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NASC.

Nascent Pharma Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
UPC	51 Neutral	$2.48M	-0.45	2.66%	―	-27.81%	―
RDHL	47 Neutral	$5.86M	―	―	―	―	―
PRFX	44 Neutral	$2.64M	―	―	―	―	―
CPHI	42 Neutral	$4.52M	-0.88	-42.47%	―	-26.92%	69.90%
SHPH	32 Underperform	$2.87M	-0.08	-9999.00%	―	―	79.31%
NASC	30 Underperform	$2.12M	-0.09	―	―	―	―